GSK and Spero Secure FDA Nod for First Oral Carbapenem
LONDON, United Kingdom, June 18, 2026 GSK plc and Spero Therapeutics have achieved a major milestone in the fight...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
LONDON, United Kingdom, June 18, 2026 GSK plc and Spero Therapeutics have achieved a major milestone in the fight...
CAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 Biogen Inc. has announced a strategic agreement to acquire RayThera Inc....
FOSTER CITY, California, United States & MUNICH, Germany, April 7, 2026 Gilead Sciences, Inc. announced a definitive agreement to...
Brisbane, California, USA, April 6, 2026 First-in-Human Study Targets Inflammation Pathways In a significant milestone for clinical-stage biotech innovation,...
San Diego & Redwood City, California, USA, April 6, 2026 Strategic Acquisition Strengthens Rare Disease Leadership In a major...
FOSTER CITY, CALIFORNIA, March 24, 2026 Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines in a...
WARREN, N.J. and ROYAL OAK, Mich., February 26, 2026 Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has signed a non-exclusive,...
Basel, Switzerland – October 30, 2025 — Roche Holding AG (SIX: RO, ROG; OTCQX: RHHBY) has successfully completed its...
